An Open-label, Fixed-sequence, Single-centre Phase I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of AZD5069 After Oral Administration of a Single Dose AZD5069 to Healthy Male Volunteers
Latest Information Update: 06 Jun 2018
At a glance
- Drugs AZD 5069 (Primary) ; Ketoconazole
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 May 2018 Results summarizing the PK profile of AZD5069 from eight phase 1 studies (NCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520; n=240) published in the Drugs in R and D
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jan 2013 New trial record